Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus

Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01686-18. doi: 10.1128/AAC.01686-18. Print 2018 Dec.

Abstract

We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.

Keywords: hepatitis B virus; pharmacokinetics; pregnancy; tenofovir.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Adult
  • Antiviral Agents / blood
  • Antiviral Agents / pharmacokinetics*
  • Antiviral Agents / pharmacology
  • Area Under Curve
  • Female
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / growth & development
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / transmission*
  • Hepatitis B, Chronic / virology
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Postpartum Period
  • Pregnancy
  • Tenofovir / blood
  • Tenofovir / pharmacokinetics*
  • Tenofovir / pharmacology
  • Viral Load / drug effects

Substances

  • Antiviral Agents
  • Hepatitis B Surface Antigens
  • Tenofovir